Brilacidin (Enema)

About Innovation Pharmaceuticals

Innovation Pharmaceuticals is a publicly traded, clinical-stage biopharmaceutical company focused on developing Brilacidin, a first-in-class defensin-mimetic with a unique multi-mechanistic profile. The company has achieved key milestones, including Fast Track designations from the FDA for COVID-19 and Oral Mucositis, a completed End-of-Phase 2 meeting for Oral Mucositis, and a licensing agreement with Alfasigma for Inflammatory Bowel Disease. Its strategy centers on advancing Brilacidin through clinical development for high-value indications while exploring portfolio diversification through its BEAMED surgical laser technology.

Therapeutic Areas